Polyantigenic interferon-γ responses are associated with protection from tb among hiv-infected adults with childhood bcg immunization

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Lahey, Timothy ^a   Mitchell, Brian K ^b   Arbeit, Robert D ^c   Sheth, Siddharth ^a,b,g   Matee, Mecky ^d   Horsburgh, C Robert ^e   MacKenzie, Todd ^a   Mtei, Lillian ^b   Bakari, Muhammad ^c   Vuola, Jenni M ^f,h   Pallangyo, Kisali ^c   von Reyn, C Fordham ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b DARTMOUTH INSTITUTE FOR HEALTH POLICY AND CLINICAL PRACTICE   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MUHIMBILI UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Tanzania)

^e BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^f NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^g LAKE ERIE COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

^h GLAXOSMITHKLINE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; GAMMA INTERFERON; PLACEBO; BACTERIAL ANTIGEN;

ADULT; ARTICLE; BCG VACCINATION; CONTROLLED STUDY; CYTOKINE RESPONSE; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RESISTANCE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; TANZANIA; TUBERCULOSIS; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; FACTUAL DATABASE; IMMUNIZATION; IMMUNOLOGY; LUNG TUBERCULOSIS; MULTIVARIATE ANALYSIS; MYCOBACTERIUM BOVIS; RISK ASSESSMENT;

MYCOBACTERIUM TUBERCULOSIS;

ADULT; ANTIGENS, BACTERIAL; CHILD; DATABASES, FACTUAL; FEMALE; HIV INFECTIONS; HUMANS; IMMUNIZATION; INTERFERON-GAMMA; MALE; MULTIVARIATE ANALYSIS; MYCOBACTERIUM BOVIS; RISK ASSESSMENT; TUBERCULOSIS, PULMONARY;

EID: 79960576471     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022074     Document Type: Article

References (49)

1. Aronson J, (1948) Protective vaccination against tuberculosis with special reference to BCG vaccination. Am Rev Tuberc 58: 255-281.
2. Ferguson R, Simes A, (1949) BCG vaccination of infant Indians in Saskatchewan. Tubercle 30: 5-11.
3. Rosenthal S, Loewinsohn E, Graham M, Liveright D, Thorne M, et al. (1960) BCG vaccination in tuberculous households. Am Rev Respir Dis 84: 690-704.
4. Black GF, Weir RE, Floyd S, Bliss L, Warndorff DK, et al. (2002) BCG-induced increase in interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomised controlled studies. Lancet 359: 1393-1401.
5. Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, et al. (1994) Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. Jama 271: 698-702.
6. Colditz GA, Berkey CS, Mosteller F, Brewer TF, Wilson ME, et al. (1995) The efficacy of bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics 96: 29-35.
7. (1999) Fifteen year follow up of trial of BCG vaccines in south India for tuberculosis prevention. Tuberculosis Research Centre (ICMR), Chennai. Indian J Med Res 110: 56-69.
8. Sterne JA, Rodrigues LC, Guedes IN, (1998) Does the efficacy of BCG decline with time since vaccination? Int J Tuberc Lung Dis 2: 200-207.
9. Aronson NE, Santosham M, Comstock GW, Howard RS, Moulton LH, et al. (2004) Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: A 60-year follow-up study. Jama 291: 2086-2091.
10. von Reyn CF, Vuola JM, (2002) New vaccines for the prevention of tuberculosis. Clin Infect Dis 35: 465-474.
11. Hoft DF, (2008) Tuberculosis vaccine development: goals, immunological design, and evaluation. Lancet 372: 164-175.
12. Kaufmann SH, Hussey G, Lambert PH, (2010) New vaccines for tuberculosis. Lancet 375: 2110-2119.
13. von Reyn CF, Mtei L, Arbeit RD, Waddell R, Cole B, et al. (2010) Prevention of tuberculosis in Bacille Calmette-Guerin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine. Aids 24: 675-685.
14. Olsen AW, Williams A, Okkels LM, Hatch G, Andersen P, (2004) Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model. Infect Immun 72: 6148-6150.
15. Kaufmann SH, (2008) Rational design of novel antibacterial vaccines with an emphasis on tuberculosis. Scand J Infect Dis 40: 595-600.
16. Flahiff EW, (1939) The occurrence of tuberculosis in persons who failed to react to tuberculin, and in persons with positive tuberculin reactions. Am Jour Hyg 30: 69-74.
17. Ziegler JE, Edwards ML, Smith DW, (1985) Exogenous reinfection in experimental airborne tuberculosis. Tubercle 66: 121-128.
18. Edwards LB, Palmer CE, (1968) Identification of the tuberculous-infected by skin tests. Ann NY Acad Sci 154: 140-148.
19. Fine PEM, (1995) Variation in protection by BCG: implications of and for heterologous immunity. Lancet 346: 1339-1345.
20. Hart PD, Sutherland I, (1977) BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life. Brit Med J 2: 293-295.
21. Opie EL, Flahiff EW, Smith HH, (1939) Protective inoculation against human tuberculosis with heat-killed tubercle bacilli. Am J Hyg 29: 155-164.
22. Weiss DW, (1959) Vaccination against tuberculosis with non-living vaccines. I. The problem and its historical background. Am Rev Respir Dis 80: 676-688.
23. Aronson JD, (1948) Protective vaccination against tuberculosis with special reference to BCG vaccination. Am Rev Tuberc 58: 255-281.
24. Ferguson RG, Simes AB, (1949) BCG vaccination of infant Indians in Saskatchewan. Tubercle 30: 5-11.
25. Rosenthal SR, Loewinsohn E, Graham ML, Liveright D, Thorne MG, et al. (1960) BCG vaccination in tuberculous households. Am Rev Respir Dis 84: 690-704.
26. Rosenthal SR, Loewinsohn E, Graham ML, Liveright D, Thorne MG, et al. (1961) BCG vaccination against tuberculosis in Chicago: a twenty year study statistically analyzed. Pediatrics 28: 622-641.
27. Levine MI, Sackett MF, (1948) Results of BCG immunization in New York City. Am Rev Tuberc. 1948;53:517-32. Am Rev Tuberc 53: 517-532.
28. Lahey T, Sheth S, Matee M, Arbeit R, Horsburgh CR, et al. (2010) Interferon gamma responses to mycobacterial antigens protect against subsequent HIV-associated tuberculosis. The Journal of infectious diseases 202: 1265-1272.
29. Munseri PJ, Talbot EA, Mtei L, Fordham von Reyn C, (2008) Completion of isoniazid preventive therapy among HIV-infected patients in Tanzania. Int J Tuberc Lung Dis 12: 1037-1041.
30. Diel R, Loddenkemper R, Meywald-Walter K, Niemann S, Nienhaus A, (2008) Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis. Am J Respir Crit Care Med 177: 1164-1170.
31. Kemp EB, Belshe RB, Hoft DF, (1996) Immune responses stimulated by percutaneous and intradermal bacille Calmette-Guerin. J Infect Dis 174: 113-119.
32. Lahey T, Matee M, Mtei L, Bakari M, Pallangyo K, et al. (2009) Lymphocyte proliferation to mycobacterial antigens is detectable across a spectrum of HIV-associated tuberculosis. BMC Infect Dis 9: 21.
33. Schwander SK, Torres M, Carranza CC, Escobedo D, Tary-Lehmann M, et al. (2000) Pulmonary mononuclear cell responses to antigens of Mycobacterium tuberculosis in healthy household contacts of patients with active tuberculosis and healthy controls from the community. J Immunol 165: 1479-1485.
34. Worku S, Hoft DF, (2000) In vitro measurement of protective mycobacterial immunity: antigen-specific expansion of T cells capable of inhibiting intracellular growth of bacille Calmette-Guerin. Clin Infect Dis 30 (Suppl 3): S257-261.
35. Selwyn PA, Hartel D, Lewis VA, Schoenbaum EE, Vermund SH, et al. (1989) A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 320: 545-550.
36. Association WM, (2006) Statement on Medical Ethics in the Event of Disaster. Pilanesberg, South Africa.
37. Karakousis PC, Bishai WR, Dorman SE, (2004) Mycobacterium tuberculosis cell envelope lipids and the host immune response. Cell Microbiol 6: 105-116.
38. Porcelli SA, Modlin RL, (1999) The CD1 system: antigen-presenting molecules for T cell recognition of lipids and glycolipids. Annu Rev Immunol 17: 297-329.
39. Abdallah AM, Gey van Pittius NC, Champion PA, Cox J, Luirink J, et al. (2007) Type VII secretion--mycobacteria show the way. Nat Rev Microbiol 5: 883-891.
40. Jouanguy E, Altare F, Lamhamedi S, Revy P, Emile JF, et al. (1996) Interferon-gamma-receptor deficiency in an infant with fatal bacille Calmette-Guerin infection. New England Journal of Medicine 335: 1956-1961.
41. Svenson S, Kallenius G, Pawlowski A, Hamasur B, (2010) Towards new tuberculosis vaccines. Human vaccines 6: 309-317.
42. Beresford B, Sadoff JC, (2010) Update on research and development pipeline: tuberculosis vaccines. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 50 (Suppl 3): S178-183.
43. Brenchley JM, Hill BJ, Ambrozak DR, Price DA, Guenaga FJ, et al. (2004) T-cell subsets that harbor human immunodeficiency virus (HIV) in vivo: implications for HIV pathogenesis. J Virol 78: 1160-1168.
44. Douek DC, Brenchley JM, Betts MR, Ambrozak DR, Hill BJ, et al. (2002) HIV preferentially infects HIV-specific CD4+ T cells. Nature 417: 95-98.
45. Geldmacher C, Schuetz A, Ngwenyama N, Casazza JP, Sanga E, et al. (2008) Early depletion of Mycobacterium tuberculosis-specific T helper 1 cell responses after HIV-1 infection. J Infect Dis 198: 1590-1598.
46. Arend SM, Geluk A, van Meijgaarden KE, van Dissel JT, Theisen M, et al. (2000) Antigenic equivalence of human T-cell responses to Mycobacterium tuberculosis-specific RD1-encoded protein antigens ESAT-6 and culture filtrate protein 10 and to mixtures of synthetic peptides. Infect Immun 68: 3314-3321.
47. Grover A, Ahmed MF, Singh B, Verma I, Sharma P, et al. (2006) A multivalent combination of experimental antituberculosis DNA vaccines based on Ag85B and regions of difference antigens. Microbes Infect 8: 2390-2399.
48. Bertholet S, Ireton GC, Kahn M, Guderian J, Mohamath R, et al. (2008) Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis. J Immunol 181: 7948-7957.
49. Agger EM, Weldingh K, Olsen AW, Rosenkrands I, Andersen P, (2002) Specific acquired resistance in mice immunized with killed mycobacteria. Scand J Immunol 56: 443-447.